Beta-propiolactone inactivation alters the structure and surface properties of coxsackievirus A16 capsids, providing important insights for the development of inactivated viral vaccines.
No takes yet. Share an insight, caveat, or question.
BPL-induced capsid changes may affect CVA16 vaccine antigenicity; hypothesis-generating for inactivation methods in enteroviral vaccines.
Ye et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: